AbCellera

AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies

Shots: AbCellera acquires TetraGenetics in an all-cash transaction that includes up front, milestones based on the achievement of technical milestones related to the development of therapeutics The acquisition will combine TetraGenetics’ capabilities with AbCellera’s technology to provides an optimized protein source for AbCellera’s Abs discovery across a range of therapeutic areas. The technology has the …

AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies Read More »

PharmaShots Weekly Snapshots (Aug 02 – 06, 2021)

Medtronic to Acquire Intersect ENT for ~$1.1B Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer Published: Aug 6, 2021 | Tags: Kite, Appia, Allogeneic Cell Therapies, Cancer Polpharma & Bioeq Report BLA Submission to the US …

PharmaShots Weekly Snapshots (Aug 02 – 06, 2021) Read More »

PharmaShots’ Key Highlights of Second Quarter 2021

The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for Molnupiravir to treat COVID-19 The big acquisition took place during the quarter including Microsoft acquired Nuance for ~$19.7B, MorphoSys acquired Constellation for ~$1.7B Our team …

PharmaShots’ Key Highlights of Second Quarter 2021 Read More »

PharmaShots Weekly Snapshots (May 03 – 07, 2021)

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer Published: May 7, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON Study, Stage IV Non-Small Cell Lung Cancer Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + …

PharmaShots Weekly Snapshots (May 03 – 07, 2021) Read More »

AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy

Shots: AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs Angios gets the rights to develop and commercialize therapeutic products resulting from the collaboration AbCellera will use an AI-powered platform to generate panels of Abs for up to three Angios-selected …

AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy Read More »

AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19

Shots: AbCellera reported that a second Ab from its collaboration with Lilly, LY-CoV1404 has entered clinical trials in patients with mild-to-moderate COVID-19. The program will join Lilly’s ongoing Blaze-4 study where it will be evaluated as monothx. and in combination with other mAbs AbCellera unveils the preclinical data demonstrating LY-CoV1404 binds to a rarely mutated …

AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19 Read More »

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications

Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead …

Gilead Expands its Collaboration with AbCellera to Develop Antibodies Against Multiple Indications Read More »

Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19

Shots: The FDA authorized EUA for bamlanivimab (700 mg) and etesevimab (1400 mg) for the treatment of mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization The EUA is based on P-III BLAZE-1 trial in ≥1,000 COVID-19 patients showed 70% reduction in hospitalizations. Lilly plans …

Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19 Read More »

Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19

Shots: The P-II/III BLAZE-1 trial involves assessing of Bamlanivimab + Etesevimab (2800 mg) vs PBO in 1035 patients recently diagnosed with COVID-19 in the ambulatory setting The results demonstrated an 70% reduction in risk of COVID-19 related hospitalizations and deaths in high-risk patients and improvements in all 2EPs including reductions in viral load and accelerated …

Eli Lilly and AbCellera Report Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV16) in P-II/III BLAZE-1 Study for Preventing COVID-19 Read More »

AI drug discovery biotech AbCellera eyes record IPO

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The Vancouver, Canada-headquartered biotech – which has been bankrolled in part by billionaire entrepreneur and venture capitalist Peter Thiel – plans to offer 23 …

AI drug discovery biotech AbCellera eyes record IPO Read More »

Lilly’s antibody for COVID-19 protection starts nursing home trial

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian biotech AbCellera – in a phase 3 trial to see …

Lilly’s antibody for COVID-19 protection starts nursing home trial Read More »